Traj52: A Protein Involved in T Cell Receptor Function and Cancer Progression

Target Name: TRAJ52

NCBI ID: G28703

TRAJ52

Other Name(s): T cell receptor alpha joining 52

Traj52: A Protein Involved in T Cell Receptor Function and Cancer Progression

Traj52, also known as T cell receptor alpha-joining 52, is a protein that is expressed in T cells, a type of immune cell that plays a crucial role in the immune system. The traj52 protein is involved in the process of cell-mediated immunity, where T cells recognize and respond to foreign antigens in the body.

One of the main functions of traj52 is its role in the process of negative selection, which is the process by which T cells decide which antigens are to be retained and which are to be rejected. This is done by the traj52 protein, which is involved in the interaction between the antigens and the T cell receptor.

Another important function of traj52 is its role in the process of clonal expansion, where T cells divide and differentiate into different cell types. This is done by the traj52 protein, which is involved in the interaction between the antigens and the T cell receptor, as well as the regulation of the cell cycle.

In addition to its role in negative selection and clonal expansion, traj52 is also involved in the process of apoptosis, where cells die and are removed from the body. This is done by the traj52 protein, which is involved in the interaction between the antigens and the T cell receptor, as well as the regulation of the apoptosis-associated protein (AP-120).

Traj52 has also been shown to play a role in cancer progression. It has been found to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that traj52 is involved in the regulation of cell signaling pathways that are often associated with cancer growth and progression.

Due to its involvement in negative selection, clonal expansion, apoptosis, and cancer progression, traj52 has potential as a drug target or biomarker. Methods such as cell-based assays and in vitro assays can be used to study the effects of drugs on traj52 and its function in these processes. This information can be used to develop new treatments for various types of cancer.

In conclusion, traj52 is a protein that is involved in a variety of processes in T cells, including negative selection, clonal expansion, apoptosis, and cancer progression. Its potential as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments for various types of cancer.

Protein Name: T Cell Receptor Alpha Joining 52

The "TRAJ52 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAJ52 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets